Tags

Type your tag names separated by a space and hit enter

Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder.
Clin Neuropharmacol 2014 Sep-Oct; 37(5):136-41CN

Abstract

OBJECTIVES

Our study aimed to identify the association of norepinephrine transporter gene (SLC6A2), synaptosomal-associated protein of the 25-kDa gene (SNAP-25), and latrophilin 3 gene (LPHN3) with osmotic-controlled release oral delivery system methylphenidate (OROS MPH) treatment response.

METHODS

One hundred thirty-nine children and adolescents with attention-deficit/hyperactivity disorder (ADHD) were recruited. We selected rs192303, rs3785143 in SLC6A2; rs3746544 (1065 T>G) in SNAP-25; and rs6551665, rs1947274, and rs2345039 in LPHN3 to examine the association of OROS MPH treatment response with each single nucleotide polymorphism. We first defined good response group when the Korean version of the ADHD rating scale score at 8 weeks was decreased for more than 50% of baseline scores and compared genotype frequencies in good response group with poor group. Second, we defined it when the Clinical Global Impression-Improvement score at 8 weeks was 1 or 2, and we also analyzed the genotype frequencies.

RESULTS

There was a significant association between the 1065 T>G of SNAP-25 gene and OROS MPH response, with the good response group defined by the Korean version of ADHD rating scale scores; 33.3% of the subjects with GG genotype showed a good response, whereas 74.7% of those with TT genotype and 72.5% of those with TG genotype showed good responses (P=0.034). SLC6A2 rs192303 was related with OROS MPH treatment response when we defined good treatment response by Clinical Global Impression-Improvement (P=0.009).

CONCLUSIONS

Our study suggested that SNAP-25 gene and SLC6A2 were involved with OROS MPH response.

Authors+Show Affiliations

*Department of Psychiatry, National Health Insurance Service, Ilsan Hospital, Goyang; †Suicide and School Mental Health Research Center, Anyang; ‡Department of Clinical pharmacology, Busan Paik Hospital, Busan; §Department of Neuropsychiatry, College of Medicine, Hallym University, Anyang; ║Department of Pharmacology, Pharmacogenomic Research Center for Membrane Transporters, Brain Korea 21 PLUS Project for Medical Science, College of Medicine, Yonsei University, Seoul; and ¶Department of Psychiatry, Bundang CHA Medical Center, School of Medicine, CHA University, Seongnam, Republic of Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25229170

Citation

Song, Jungeun, et al. "Association of SNAP-25, SLC6A2, and LPHN3 With OROS Methylphenidate Treatment Response in Attention-deficit/hyperactivity Disorder." Clinical Neuropharmacology, vol. 37, no. 5, 2014, pp. 136-41.
Song J, Kim SW, Hong HJ, et al. Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder. Clin Neuropharmacol. 2014;37(5):136-41.
Song, J., Kim, S. W., Hong, H. J., Lee, M. G., Lee, B. W., Choi, T. K., ... Yook, K. H. (2014). Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder. Clinical Neuropharmacology, 37(5), pp. 136-41. doi:10.1097/WNF.0000000000000045.
Song J, et al. Association of SNAP-25, SLC6A2, and LPHN3 With OROS Methylphenidate Treatment Response in Attention-deficit/hyperactivity Disorder. Clin Neuropharmacol. 2014;37(5):136-41. PubMed PMID: 25229170.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder. AU - Song,Jungeun, AU - Kim,So Won, AU - Hong,Hyun Ju, AU - Lee,Min Goo, AU - Lee,Byoung Wook, AU - Choi,Tai Kiu, AU - Lee,Sang-Hyuk, AU - Yook,Ki-Hwan, PY - 2014/9/18/entrez PY - 2014/9/18/pubmed PY - 2015/6/5/medline SP - 136 EP - 41 JF - Clinical neuropharmacology JO - Clin Neuropharmacol VL - 37 IS - 5 N2 - OBJECTIVES: Our study aimed to identify the association of norepinephrine transporter gene (SLC6A2), synaptosomal-associated protein of the 25-kDa gene (SNAP-25), and latrophilin 3 gene (LPHN3) with osmotic-controlled release oral delivery system methylphenidate (OROS MPH) treatment response. METHODS: One hundred thirty-nine children and adolescents with attention-deficit/hyperactivity disorder (ADHD) were recruited. We selected rs192303, rs3785143 in SLC6A2; rs3746544 (1065 T>G) in SNAP-25; and rs6551665, rs1947274, and rs2345039 in LPHN3 to examine the association of OROS MPH treatment response with each single nucleotide polymorphism. We first defined good response group when the Korean version of the ADHD rating scale score at 8 weeks was decreased for more than 50% of baseline scores and compared genotype frequencies in good response group with poor group. Second, we defined it when the Clinical Global Impression-Improvement score at 8 weeks was 1 or 2, and we also analyzed the genotype frequencies. RESULTS: There was a significant association between the 1065 T>G of SNAP-25 gene and OROS MPH response, with the good response group defined by the Korean version of ADHD rating scale scores; 33.3% of the subjects with GG genotype showed a good response, whereas 74.7% of those with TT genotype and 72.5% of those with TG genotype showed good responses (P=0.034). SLC6A2 rs192303 was related with OROS MPH treatment response when we defined good treatment response by Clinical Global Impression-Improvement (P=0.009). CONCLUSIONS: Our study suggested that SNAP-25 gene and SLC6A2 were involved with OROS MPH response. SN - 1537-162X UR - https://www.unboundmedicine.com/medline/citation/25229170/Association_of_SNAP_25_SLC6A2_and_LPHN3_with_OROS_methylphenidate_treatment_response_in_attention_deficit/hyperactivity_disorder_ L2 - http://Insights.ovid.com/pubmed?pmid=25229170 DB - PRIME DP - Unbound Medicine ER -